[Generation of HER2 specific, HLA-A24 restricted CTLs derived from a healthy donor].
Cancer vaccine therapy is one of the latest treatment modalities for advanced cancer. In this study, we have newly identified two HER2 peptide epitopes restricted by HLA-A24, which are the most common alleles in Japanese. We have generated mature DCs from PBMCs in the HLA-A24+ healthy donor. Mature DCs were co-incubated with HER2 peptide, and then autologous PBMCs were co-incubated with antigen-loaded DCs. In this way, we have generated HER2 reactive and HLA-A24-restricted CTL lines. The CTL's specificity was evaluated with ELISPOT analysis and cytotoxic assay. In the two CTL lines, the specificity of TISI loaded with HER2/neu peptide used for each CTL induction was recognized, and that specific cytotoxicity was also found against cancer cell lines expressing HLA-A24 and HER2. In conclusion, we have newly identified two HER2 peptide epitopes restricted by HLA-A24 and confirmed that these epitopes will be new targets for cancer vaccine therapy.
Mimura
Kousaku
K
First Dept. of Surgery, Yamanashi University.
Kono
Koji
K
Miyagawa
Naoto
N
Omata
Hideo
H
Sugai
Hidemitsu
H
Fujii
Hideki
H
D019496:Cancer Vaccines / Q000276:immunology*; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000302:isolation & purification*; D018734:Genes, erbB-2 / Q000276:immunology*; D015234:HLA-A Antigens / Q000276:immunology*; D059871:HLA-A24 Antigen; D006801:Humans
D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D015234:HLA-A Antigens; D059871:HLA-A24 Antigen